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Two hundred twenty-one isolates of Acinetobacter baumannii and 15 of Acinetobacter genospecies 3 (AG3)
were consecutively collected in a 30-day period during the nationwide project GEIH-Ab2000. Nosocomial
acquisition (P  0.01), intensive care unit admission (P  0.02), and antibiotic pressure (P  0.03) were
observed to be lower in the AG3 group. AG3 isolates were more frequently implied in wound infections
(P  0.05), while A. baumannii tended to be recovered from respiratory samples (P  0.08). To our
knowledge, this is the first report analyzing the clinical differences among Acinetobacter genospecies, with
our findings suggesting that clinical features of AG3 may not be equivalent to those traditionally described
for A. baumannii.
Among the species in the Acinetobacter genus, Acinetobacter
baumannii is the most frequently isolated in clinical samples
and the one of greatest clinical interest. However, since mo-
lecular tools are not usually available for routine clinical prac-
tice, other Acinetobacter species with similar phenotypes are
usually misidentified as A. baumannii. When the prevalence of
these genospecies is assessed with genetic tools, many authors
identify Acinetobacter genospecies 3 as the most commonly
isolated species after A. baumannii or even the most frequently
isolated (2, 13). Nonetheless, despite its remarkable preva-
lence, clinical data regarding infections produced by Acineto-
bacter genospecies 3 are scarce (8, 9).
The present study aimed to describe the clinical features of
colonization and infections by Acinetobacter genospecies 3 and
their differences from those of A. baumannii.
Twenty-eight Spanish hospitals participated in the GEIH-
Ab2000 project in November 2000. During a 30-day period, all
new isolates of A. baumannii were included and sent to a
reference laboratory. Bacterial identification at the genus level
was performed following conventional phenotypic methods
(5), whereas identification of the genospecies was determined
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by amplified rRNA gene restriction analysis and by DNA se-
quencing of the 16S rRNA gene (1). For each case, only the
first isolate was studied.
For each case, the following variables were recorded: hos-
pital ward, gender, age, type of sample, underlying diseases,
invasive procedures, and antimicrobial agents received dur-
ing the previous month. A. baumannii was considered to
have been nosocomially acquired if the sample had been
obtained more than 2 days after the patient’s admission. The
clinical significance (colonization or infection) of the A.
baumannii isolation and type of infection in each case was
assessed according to Centers for Disease Control and Pre-
vention criteria (6, 7). Sepsis, severe sepsis, septic shock,
and multiorgan failure were defined according to standard
criteria. Patients were observed until discharge or death or
until 30 days after the sample had been obtained if the
patient was still hospitalized.
Paired categorical and continuous variables were com-
pared using 2 or Fisher’s exact test and the Mann-Whitney
U test, respectively. Significance was set at a P value of
0.05. Statistical analyses were performed with SPSS v.15.0.
Separate data obtained from this project have been pub-
lished elsewhere (1, 4, 5, 10–12).
During the study period, 240 isolates presumptively iden-
tified as A. baumannii by local laboratories were sent to the
reference laboratory: 221 were identified as A. baumannii,
15 as Acinetobacter genospecies 3, and 3 as other Acineto-
bacter species, and 1 case was not an Acinetobacter species
(12). In the A. baumannii and Acinetobacter genospecies 3
groups, 9 and 2 cases, respectively, were excluded due to
lack of data essential to the study. Therefore, 212 cases of A.
baumannii (AB group) and 13 cases of Acinetobacter geno-
species 3 (AG3 group) were included. No case aggregation
was observed for Acinetobacter genospecies 3 isolates, which
came from 10 different hospitals.
The main clinical data are summarized in Table 1.
Most samples in the AG3 group were recovered from
patients admitted in non-intensive care unit (ICU) wards
(n  11; 69.2%), and 23.1% of samples corresponded to
outpatients (n  3, including 1 urine culture, 1 wound exu-
date swab, and the ascitic fluid from a patient receiving
peritoneal dialysis). Most isolates were recovered from
wound swab or abscess culture (n  6; 46.1%), and infec-
tions were usually located on skin and soft tissues (57.1% of
cases with infection; n  4). No cases in this group devel-
oped severe sepsis or septic shock, and only one patient,
who was colonized only by Acinetobacter genospecies 3,
died.
These features differ from those observed for patients
with A. baumannii isolates. ICU admission (15.4% versus
50%) and nosocomial acquisition (76.9% versus 97.2%)
were both significantly higher in the AB group, and the
median number of antimicrobial agents previously adminis-
tered was also superior (P  0.03). A. baumannii preferably
colonized or infected the respiratory tract, but this trend did
not reach statistical significance. No significant differences
were observed regarding mortality or severity of episodes of
infection, although they both were higher in the AB group.
To our knowledge, this is the first study specifically de-
scribing the clinical features of infection and colonization by
Acinetobacter genospecies 3 and their differences from those
of A. baumannii. Only two studies have reported limited
clinical data about Acinetobacter genospecies 3. Idzenga et
al. (9) described an outbreak of this genospecies in four
patients from a Dutch ICU. Clinical information is scarce,
since authors focus on demonstrating the cross-transmission
of the pathogen and its microbiologic features. Horrevorts
et al. (8) prospectively included 56 isolates of Acinetobacter
spp. from a neonatal ICU. DNA-DNA hybridization tests
were performed on 38 of them, with 76.3% being identified
as Acinetobacter genospecies 3. The clinical information pro-
vided refers to the whole sample, not specifically to geno-
species 3 cases. Moreover, this information might be limited
to a specific population (critically ill neonates) and to the
epidemiologic circumstances of the health center itself.
Clinical differences among genospecies were not assessed in
any of these reports.
In our study, the clinical profile of patients colonized or
infected by Acinetobacter genospecies 3 was noticeably differ-
ent from that observed for patients with A. baumannii infec-
tions. Nosocomial acquisition was not so frequent and, when it
was described, usually occurred in conventional wards, not in
ICUs. Therefore, antibiotic pressure on the AG3 group was
markedly inferior. Acinetobacter genospecies 3 was more fre-
quently implied in skin and soft tissue infections, including
surgical wound infection, while colonization and infection of
the respiratory tract seemed to be less frequent than that
observed for A. baumannii. We also found a nonsignificant
trend suggesting a better prognosis for infections by Acin-
etobacter genospecies 3, though this fact was probably con-
ditioned by the type of infections observed in this group and
the higher rate of inappropriate empirical treatment in the
AB group. Nevertheless, some authors have suggested that
there might be relevant pathogenic differences among the
genospecies of Acinetobacter (3).
The prevalence of Acinetobacter genospecies 3 in our
study (15/240; 6.25%) is considerably lower than that ob-
served by other authors (2, 13), who have described preva-
lences of up to 39%. The differences probably lie in the
specific epidemiologic situation of each center.
This new clinical information seems to provide a proper
context for microbiologic data published so far. We and
other authors previously reported better antimicrobial sus-
ceptibility for Acinetobacter genospecies 3 than for A. bau-
mannii (10, 13). These differences might arise from a dif-
ferent ecology and pathogenesis, as suggested by our results.
The study has some limitations. The size of the AG3
group is relatively small and might be underpowered for
evaluating certain differences. Moreover, the results ob-
served in our sample might conflict with the clinical situa-
tion in other geographic areas or even in different epidemi-
ologic circumstances. However, the multicentric, nationwide
design of the study aims to provide the results with a
broader perspective. We cannot define if the three cases of
Acinetobacter cenospecies 3 isolated in outpatients were true
community-acquired infections or were related to health
care assistance, since this concept was not defined at the
time the study was performed. Finally, the study was carried
out 10 years ago, and there may be some differences from
the current epidemiologic situation. However, the value of
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this study lies in the novel report of qualitatively different
clinical features of the infections produced by other geno-
species of Acinetobacter, which may not be equivalent to
those traditionally described for A. baumannii. This consti-
tutes an interesting starting point for future, larger studies,
which would be necessary to confirm these findings.
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